Trendlines Group Ltd. · SGX:42T
Trendlines — The Trendlines Group — Investor Presentation (February 2026)
21 slides from Trendlines's investor presentation, February 2026
Slide 1: Succeeding Together
Succeeding Together Transforming futures in medtech & agrifood February 2026
Slide 2: Legal disclaimer
Legal disclaimer Important notice This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 3: Who we are
The Trendlines Group (SGX: 42T; OTCQX: TRNLY) invests in agrifood and medtech innovative companies from seed to market. Based in Israel and Singapore, we combine capital, expertise, and partnerships to drive impactful technologies, empower entrepreneurs, and create long-term value for our investors
Slide 4: Leadership
Leadership Haim Brosh Barak Singer Orit Alaluf Cohen Executive Director & Executive VP & Head of Chief Financial Officer Steve Rhodes CEO Healthcare Founder & Chair Emeritus 25 years’ managerial Broad experience in all Trendlines’ Founder; over and financial Extensive investment financial functions,
Slide 5: Board of Directors
Board of Directors Nehama Ronen Sin Boon Ann Haim Brosh Chair Independent Director Executive Director & CEO 25 years’ experience in public companies. 30 years’ experience 25 years’ managerial She was Director working in the legal and financial General of Israel’s industry and serving experience in p
Slide 6: A taste of our portfolio companies
A taste of our portfolio 41 companies * portfolio 12 29 agrifood medtech * including the 8 consolidated portfolio companies in Singapore 6
Slide 7: Portfolio cluster values
Portfolio cluster values Non-IFRS* Value of Trendlines’ Fair Value of Trendlines’ Cluster Share (US$'000) Share (additional information) (US$'000) 31.12.2025 Aquaculture & Animal Health US$ 1,247 US$ 2,261 Crop Protection US$ 5,747 US$ 11,589 Future Food & Ingredients US$ 12,831 US$ 20,335 Digitizat
Slide 8: The natural food color revolution
The natural food color revolution A broad-spectrum of healthy plant-based colors produced via Founded 2018; fermentation technology, using baker’s yeast as a biofactory. Yokne’am Illit, IL Phytolon’s high-quality and cost-effective pigments offer value for CEO consumers, the environment and food ind
Slide 9: 4 more agrifood frontrunners
4 more agrifood frontrunners 12 agrifood portfolio companies Phage-based solutions for crop Cultivating high quality and high Nanobody-based biological insect Oral delivery platform for the disease control that target bacteria value cocoa ingredients using cell control to uniquely target the prevent
Slide 10: Cryotherapy treatment for urological non-muscle invasive bladder cancer (NIMBC)
Cryotherapy treatment for urological non- muscle invasive bladder cancer (NIMBC) A new ablative approach for the treatment of urological tissue with cryotherapy. Founded 2015 CEO Eyal Kochavi Achievements IP Submitted national • Closed US$16.5 million investment round including phase and PCT strateg
Slide 11: 4 more leading medtech companies
4 more leading medtech companies 29 medtech portfolio companies Minimally invasive, nonsurgical, Endoscopic ultrasound fine needle Next-generation aspiration catheter A small, game-changing incision-free and mesh-free repair biopsy system for improve, precise for treating ischemic stroke. device to
Slide 12: FY 2025 financials
FY 2025 financials 12
Slide 13: Balance sheet
Balance sheet Assets (US$’000) Liabilities & Equity (US$’000) Current assets 31 Dec 2025 31 Dec 2024 Current liabilities 31 Dec 2025 31 Dec 2024 Cash and cash equivalents 4,,817 4,973 Lease liability 271 304 Short-term bank deposits 110 1,014 Short-term loan 1,414 423 Accounts and other Trade and ot
Slide 14: Profit and Loss Statements
Profit and Loss Statements (US$’000) Income 31 December 2025 31 December 2024 Gain/(Loss)from change in fair value of investments in portfolio companies 7,127 (3,126) Income from services to portfolio companies 266 1,494 Income from contracted R&D services 84 225 Financial income 236 514 Other incom
Slide 15: 2024-2025 Corporate Achievements
2024-2025 Corporate Achievements • Raised ~$25 million for Trendlines • Raised ~$100 million for Trendlines portfolio companies • Reduced operating costs by 50% • Focus, focus, focus >> Consolidated activities to focus on core business: o Sale of Labs unit o Transfer of Fund management activities o
Slide 16: 2024-5 Portfolio Achievements
2024-5 Portfolio Achievements • Raised ~100 million for our portfolio companies over 2 years. • Significant portfolio progress: ✓ Phytolon • Hit full-project milestone tripling manufacturing efficiency with Ginkgo Bioworks • Secured funding from Rich Product Ventures, Colorcon and additional strateg
Slide 17: 2024-5 Portfolio Achievements
2024-5 Portfolio Achievements • Significant portfolio progress: ✓ Vessi Medical • Closed $16.5 Million Series A Round for innovative cryotherapy urological treatment • On going new clinical study in Spain and Israel with positive results ✓ IBI-Ag • Completed $10 million Series A round led by Corteva
Slide 18: 2024-5 Portfolio Achievements
2024-5 Portfolio Achievements • Significant portfolio progress: ✓ Ceretrieve • On going new clinical study in Europe (Germany, Portugal) with successful results • Raised additional $3million in 2025 from investors and from a new IIA grant ✓ Vensica Medical • Closed a $11million financing round inclu
Slide 19: 2024-5 Portfolio Achievements
2024-5 Portfolio Achievements • Significant portfolio progress: ✓ BeCapio • On-going successful clinical trial ✓ AgroScout • Signed global contract with PepsiCo ✓ Sol Chip • Signed contract with German real estate leader ✓ Dasyo • Completed initial U.S. study for safety with efficacy indications • S
Slide 20: Thank you
THANK YOU +972.72.260.7000 | www.trendlines.com
Slide 21: Notes and Disclaimer
Notes and Disclaimer The non-IFRS fair value information does not represent any forecast or future performance but serves as an extra aid in evaluating our portfolio companies and investment approaches. The additional information (Non-IFRS value) which, as stated, differs from the IFRS fair value at
The Trendlines Group — Investor Presentation (February 2026) on 6ix